Leukemia Clinical Trials in New York

Showing 1061-1080 of 1,787 trials

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

NCT03761069

This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory acute myeloid leukemia (AML) who have exhausted standard available therapies known to provide clinical benefit. The study is designed as a series of cohort-based dose escalations. For each cohort, a minimum of 3 evaluable participants with PK and safety data will be assessed. Additional participants will be recruited if additional PK data are needed to assess mean exposure based on the observed variability.

Leukemia, Myeloid, AcuteAML

PTC Therapeutics33 participantsStarted Oct 2018

Aurora, Colorado, United States • New Haven, Connecticut, United States • Detroit, Michigan, United States +14 more locations

COMPLETEDPhase 1< 1 mile

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577

The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.

Kidney CancerHead and Neck CancerBreast Cancer+6 more

Weill Medical College of Cornell University20 participantsStarted Jul 2009

New York, New York, United States

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Leukemia Trials in Other Cities

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Double Cord Versus Haploidentical (BMT CTN 1101)

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

Drug Challenges Without Prior Skin Testing

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

DOSE Trial of Opioid Sparing Effect

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Other Conditions in New York